Neurological disease biotech Longboard Pharmaceuticals files for an $86 million IPO

Longboard Pharmaceuticals, a phase 1 biotech formed by Arena Pharmaceuticals developing medicines for neurological diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering.

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical comRead More